Generate:Biomedicines announced initiation of two large Phase 3 trials for its lead TSLP antibody, advancing the company’s first program from discovery to pivotal development. The move underscores the company’s transition from AI‑driven target discovery to late‑stage clinical execution. Management framed the studies as a validation of its platform’s ability to produce clinical candidates, and said the Phase 3 programs will test efficacy and safety across broader patient populations than previous Phase 2 work.